Eric J. Sherman

14.9k total citations · 5 hit papers
269 papers, 8.6k citations indexed

About

Eric J. Sherman is a scholar working on Otorhinolaryngology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Eric J. Sherman has authored 269 papers receiving a total of 8.6k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Otorhinolaryngology, 107 papers in Oncology and 105 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Eric J. Sherman's work include Head and Neck Cancer Studies (113 papers), Thyroid Cancer Diagnosis and Treatment (69 papers) and Lung Cancer Treatments and Mutations (51 papers). Eric J. Sherman is often cited by papers focused on Head and Neck Cancer Studies (113 papers), Thyroid Cancer Diagnosis and Treatment (69 papers) and Lung Cancer Treatments and Mutations (51 papers). Eric J. Sherman collaborates with scholars based in United States, France and China. Eric J. Sherman's co-authors include David G. Pfister, Nancy Y. Lee, Alan L. Ho, Matthew G. Fury, Harry Quon, Gregory S. Weinstein, Nadeem Riaz, Sofia Haque, R. Michael Tuttle and Nora Katabi and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Eric J. Sherman

251 papers receiving 8.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522

2014 578 citations Eric J. Sherman et al. Journal of Clinical Oncology profile →
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer

2013 555 citations Alan L. Ho, Eric J. Sherman et al. profile →
Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

2008 494 citations Ezra E.W. Cohen, Lee S. Rosen et al. Journal of Clinical Oncology profile →
Transoral Robotic Surgery

2007 445 citations Gregory S. Weinstein, Eric J. Sherman et al. profile →
Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma

2020 264 citations Sean M. McBride, Eric J. Sherman et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Eric J. Sherman

Since Specialization

Citations

This map shows the geographic impact of Eric J. Sherman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric J. Sherman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric J. Sherman more than expected).

Fields of papers citing papers by Eric J. Sherman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric J. Sherman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric J. Sherman. The network helps show where Eric J. Sherman may publish in the future.

Co-authorship network of co-authors of Eric J. Sherman

This figure shows the co-authorship network connecting the top 25 collaborators of Eric J. Sherman. A scholar is included among the top collaborators of Eric J. Sherman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric J. Sherman. Eric J. Sherman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pathologic Response to Neoadjuvant Cetuximab, Platinum, and Taxane in Locally Advanced HNSCC 2025 ·Otolaryngology ·Gabriel Raab, Bin Xu, (unknown), Nora Katabi, Snjezana Doğan, Lara Dunn, Snehal G. Patel, Eric J. Sherman, David G. Pfister, (unknown), (unknown), Ronald Ghossein, Jennifer R. Cracchiolo, Alan L. Ho, Ian Ganly, Winston Wong	0
2	Updated Estimates of Patients With Oropharyngeal Cancer in the US 2025 ·JAMA Network Open ·(unknown), Anna Lee, Jung Julie Kang, Irini Youssef, Kaveh Zakeri, Edward Christopher Dee, Nadeem Riaz, A. Shamseddine, Yao Yu, Jennifer Ma, (unknown), Marc A. Cohen, Jennifer R. Cracchiolo, Richard J. Wong, Winston Wong, Lara Dunn, Eric J. Sherman, (unknown)	0
3	Proton Therapy for Paranasal Sinus Cancer: Clinical Outcomes and Patterns of Failure 2025 ·Head & Neck ·(unknown), (unknown), Nadeem Riaz, Sean M. McBride, Daphna Y. Gelblum, A. Shamseddine, Marc A. Cohen, Richard J. Wong, Jennifer R. Cracchiolo, Ian Ganly, Eric J. Sherman, Alan L. Ho, Winston Wong, Lara Dunn, (unknown)	0
4	The Use of Proton Radiation in the Management of Adenoid Cystic Carcinoma 2025 ·International Journal of Particle Therapy ·(unknown), A. Shamseddine, (unknown), (unknown), Kaveh Zakeri, Yao Yu, Linda Chen, Daphna Y. Gelblum, Sean M. McBride, Nadeem Riaz, Eric J. Sherman, Richard Wong, Marc A. Cohen, Loren S. Michel, Ian Ganly, Lara Dunn, Alan L. Ho, Zhigang Zhang, (unknown), Nancy Y. Lee	0
5	A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer 2024 ·Oral Oncology ·Antoine Desîlets, David G. Pfister, Sarah Stein, Winston Wong, Eric J. Sherman, James Fetten, (unknown), Anuja Kriplani, Lara Dunn, Alan L. Ho, Loren S. Michel	4
6	Comparative patient-reported tolerability (PRT): A multiplicity-controlled analysis of LIBRETTO-531, a randomized controlled trial (RCT) in medullary thyroid cancer (MTC). 2024 ·Journal of Clinical Oncology ·Marcia S. Brose, Bruce Robinson, Lori J. Wirth, Jaume Capdevila, Jonathan Wadsley, Eric J. Sherman, Makoto Tahara, (unknown), Mimi I. Hu, Ming Gao, Fernanda Vaisman, (unknown), Boris K. Lin, Patricia Maeda, Adrienne M. Gilligan, Yan Lin, Nalin Payakachat, Julien Hadoux, Rossella Elisei	3
7	Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer 2024 ·The Journal of Clinical Endocrinology & Metabolism ·Bhavana Konda, Eric J. Sherman, Erminia Massarelli, Jorge J. Nieva, Jameel Muzaffar, (unknown), Mabel Ryder, Alan L. Ho, Mark Agulnik, Lai Wei, (unknown), (unknown), (unknown), John Wright, Howard Streicher, William E. Carson, Manisha H. Shah	4
8	Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer 2023 ·Head & Neck ·James E. Han, Kaveh Zakeri, Gabriel Raab, (unknown), A. Shamseddine, Linda Chen, Yao Yu, Jung Julie Kang, Sean M. McBride, Nadeem Riaz, C. Jillian Tsai, Daphna Y. Gelblum, Eric J. Sherman, Richard J. Wong, Loren S. Michel, Nancy Y. Lee	7
9	922P Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma 2023 ·Annals of Oncology ·Glenn J. Hanna, John M. Kaczmar, Dan P. Zandberg, Deborah Jean Lee Wong, Emrullah Yilmaz, Eric J. Sherman, (unknown), Assuntina G. Sacco, David F. Bohr, (unknown), Sanela Bilic, Rachel Salazar, (unknown), Christine H. Chung	3
10	A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer. 2023 ·Journal of Clinical Oncology ·Antoine Desîlets, David G. Pfister, Winston Wong, Eric J. Sherman, James Fetten, (unknown), Lara Dunn, Alan L. Ho, Loren S. Michel	2
11	Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity 2021 ·Molecular Cancer Therapeutics ·Yiyu Dong, Yongxing Gong, Fengshen Kuo, Vladimir Makarov, Ed Reznik, Gouri J. Nanjangud, Ömer Aras, HuiYong Zhao, Rui Qu, James A. Fagin, Eric J. Sherman, Bin Xu, Ronald Ghossein, Timothy A. Chan, Ian Ganly	4
12	The effect of short radiation treatment breaks on chemo‐radiotherapy for oropharyngeal cancers 2021 ·Head & Neck ·(unknown), Jung Julie Kang, Anna Lee, Sarin Kitpanit, Ming Fan, (unknown), (unknown), Kaveh Zakeri, Daphna Y. Gelblum, Eric J. Sherman, Lara Dunn, Jay Boyle, Richard J. Wong, Linda Chen, Yao Yu, Sean M. McBride, C. Jillian Tsai, Nadeem Riaz, Nancy Y. Lee	1
13	Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer 2021 ·Journal of Clinical Oncology ·Lori J. Wirth, Marcia S. Brose, Eric J. Sherman, Lisa Licitra, Martin Schlumberger, Steven I. Sherman, Keith C. Bible, Bruce Robinson, Patrice Rodien, Yann Godbert, Christelle de la Fouchardière, Kate Newbold, Christopher M. Nutting, Soamnauth Misir, Ran Xie, (unknown), (unknown), Maria E. Cabanillas	83
14	Outcomes and prognostic factors of major salivary gland tumors treated with proton beam radiation therapy 2021 ·Head & Neck ·Kaveh Zakeri, (unknown), Jung Julie Kang, Anna Lee, Paul B. Romesser, (unknown), Daphna Y. Gelblum, Eric J. Sherman, Lara Dunn, Jay Boyle, Richard J. Wong, Linda Chen, Yao Yu, C. Jillian Tsai, Sean M. McBride, Nadeem Riaz, Nancy Y. Lee	12
15	Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma breakdown → 2020 ·Journal of Clinical Oncology ·Sean M. McBride, Eric J. Sherman, C. Jillian Tsai, Shrujal S. Baxi, Jahan Aghalar, Juliana Eng, Wanqing Iris Zhi, Daniel C. McFarland, Loren S. Michel, Robert J. Young, Robert A. Lefkowitz, D. Spielsinger, Zhigang Zhang, Jessica Flynn, Lara Dunn, Alan L. Ho, Nadeem Riaz, David G. Pfister, Nancy Y. Lee	264
16	Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers 2020 ·Cancer Discovery ·Vivek Subbiah, Igor Puzanov, Jean‐Yves Blay, Ian Chau, A. Craig Lockhart, Noopur Raje, Juergen Wolf, José Baselga, Funda Meric‐Bernstam, Jason Roszik, Eli L. Diamond, Gregory J. Riely, Eric J. Sherman, Todd Riehl, Bethany Pitcher, David M. Hyman	86
17	Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies 2020 ·Thyroid ·(unknown), (unknown), Eric J. Sherman, R. Michael Tuttle, Mona M. Sabra	19
18	Number of Lymph Nodes Examined Is Associated With Overall Survival in Clinically Node-Negative Oral Cavity Cancer Patients Receiving Definitive Surgery—A Population-Based Analysis Using the National Cancer Data Base 2016 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), Sean M. McBride, Nadeem Riaz, Jonathan E. Leeman, Benjamin R. Roman, Shrujal S. Baxi, Eric J. Sherman, Richard J. Wong, (unknown)	1
19	Diffusion-Weighted Magnetic Resonance Imaging for Predicting and Detecting Early Response to Chemoradiation Therapy of Squamous Cell Carcinomas of the Head and Neck 2009 ·Clinical Cancer Research ·Sungheon Kim, Laurie A. Loevner, Harry Quon, Eric J. Sherman, Gregory S. Weinstein, Alex Kilger, Harish Poptani	319
20	Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study breakdown → 2008 ·Journal of Clinical Oncology ·Ezra E.W. Cohen, Lee S. Rosen, Everett E. Vokes, Merrill S. Kies, Arlene A. Forastiere, Francis P. Worden, Madeleine Kane, Eric J. Sherman, Sinil Kim, Paul Bycott, Michael A. Tortorici, David R. Shalinsky, Katherine Liau, Roger B. Cohen	494

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact